argenx SE (ARGX) stock

ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 19, 2026Score 5/30

$981.33+3.75 (+0.38%)

Close on Nov 12, 2026Market cap –P/E 50.1Yield –

argenx gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2023 it was -231.6%, against -193.5% the year before.

Period	Period end	Value	Change (pts)
FY2023	Dec 31, 2023	-231.6%	−38.1
FY2022	Dec 31, 2022	-193.5%	–

See a number that looks wrong?